Empfehlung
6,7
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
53.3
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Stammdaten
Unternehmen
| Name | KALA BIO, Inc. |
|---|---|
| Ticker | KALA |
| CIK | 0001479419 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | KALA BIO, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 21:32:45.021938 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-12-31 | 10-K | -38,511,000 | -10.15 | 55,483,000 | 12,332,000 | |
| 2017-12-31 | 10-K | 0 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -967 | 0.82 | -792.94 | -1,6% | |
| 2025-10-23 | Iwicki Mark T | Director | Open Market Sale | -154,894 | 0.81 | -125,464.14 | -246,7% | |
| 2025-10-23 | Iwicki Mark T | Director | Open Market Sale | -154,894 | 0.81 | -125,464.14 | -246,7% | |
| 2025-10-22 | Kharabi Darius | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -20,806 | 0.83 | -17,268.98 | -34,0% | |
| 2025-10-22 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -32,230 | 0.83 | -26,750.90 | -52,6% | |
| 2025-10-22 | Bazemore Todd | Director | Open Market Sale | -47,768 | 0.83 | -39,647.44 | -78,0% | |
| 2025-10-22 | Brazzell Romulus K | Officer, SEE REMARKS | Open Market Sale | -46,748 | 0.83 | -38,800.84 | -76,3% | |
| 2025-06-24 | Iwicki Mark T | Director | Open Market Sale | -13,227 | 4.01 | -53,040.27 | -104,3% | |
| 2025-06-03 | Iwicki Mark T | Director | Open Market Sale | -10,866 | 3.74 | -40,638.84 | -79,9% | |
| 2025-06-03 | Iwicki Mark T | Director | Open Market Sale | -10,866 | 3.74 | -40,638.84 | -79,9% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.